Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Pharma Industry Associations Air Their Concerns Following Rejection of Brexit Deal

Posted on January 23rd, 2019 by in Pharma R&D

Brexit New

There has always been a special relationship between the United States and the United Kingdom that gives the two nations a unique connection. Unfortunately, lately, the two have also shared quite a bit of upheaval and uncertainty in their respective governments.

(more…)

Avoiding Pitfalls and Costly Mistakes in Early Stage R&D

Posted on January 17th, 2019 by in Pharma R&D

Pharma R&D costs continue to rise rapidly. A well-known Tufts study estimated the average pre-tax cost per new approved prescription drug (including failures and capital costs) was nearly $2.6 billion in 2013. However, the creation of novel approved drugs has not kept up with investment over the past two decades. (more…)

Emulating start-up success with purpose-built data tools

Posted on December 12th, 2018 by in Pharma R&D

Innovation used to be almost solely accredited to Big Pharma, but many of the more established businesses in the industry are finding that their rate of discovery is slowing as they try to find answers to some the industry’s biggest problems, such as antibiotic resistance. (more…)

Small Biotechs Progressing Beyond Startup Status

Posted on November 29th, 2018 by in Pharma R&D

When is a startup no longer a startup? Small biotech companies armed with a talented crop of scientists have been springing up all across the pharma landscape for the last several years, establishing buzzing hubs of innovation. Not all of them find their research efforts successful, but many do and then go on to be acquired by larger pharmaceutical firms that have the resources to bring their ideas to fruition. (more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5